The earnings call presented strong revenue growth and strategic progress, particularly in the MedTech segment and international expansion. Despite challenges such as tariff impacts and a decrease in NanoKnife capital sales, the company demonstrated positive financial performance and a robust future growth outlook.

Company Guidance

During the AngioDynamics Fiscal Year 2025 Fourth Quarter Earnings Call, the company reported a strong performance with total revenue reaching $80.2 million, marking a 12.7% year-over-year growth. This was driven by a 22% increase in their MedTech segment and a 6.2% rise in med device sales. Auryon, their leading MedTech product, contributed $15.6 million, growing 19.7% compared to the previous year, while the mechanical thrombectomy segment, comprising AngioVac and AlphaVac, saw a notable 44.7% year-over-year growth. The company also achieved gross margins of 52.7% despite a negative tariff impact, which amounted to $1.6 million in expenses during the quarter. For fiscal year 2026, AngioDynamics anticipates net sales growth of 4% to 6%, with MedTech sales expected to grow by 12% to 15%. They project gross margins between 53.5% and 55.5%, inclusive of a $4 to $6 million tariff impact, and aim to maintain positive cash flow throughout the year. The company remains focused on operational efficiency and strategic growth within their innovative MedTech platforms, positioning them well for future expansion.

Strong Revenue Growth

Total revenue for Q4 2025 was $80.2 million, representing a growth of over 12% year-over-year, led by MedTech growth of over 20% and med device growth of more than 6%.

MedTech Portfolio Success

Auryon, the largest MedTech product line, delivered its sixteenth consecutive quarter of double-digit growth, with $185 million in cumulative sales since launch.

International Expansion

Auryon received CE Mark approval in September 2024, opening the European PAD market, generating over $1 million in revenue from Europe in Q4 2025.

Mechanical Thrombectomy Portfolio Growth

The mechanical thrombectomy portfolio, including AngioVac and AlphaVac, grew approximately 45% year-over-year in Q4 2025.

NanoKnife Achievements

NanoKnife met primary effectiveness endpoints in trials and received a CPT Category I code for prostate and liver treatments, effective January 2026.

Positive Financial Performance

Adjusted EBITDA for Q4 2025 was $3.4 million, compared to $1.5 million in Q4 2024, and free cash flow generation was over $15 million.

Future Growth Outlook

Guidance for fiscal year 2026 anticipates net sales growth of 4% to 6%, with MedTech segment growth of 12% to 15%.

AngioDynamics (ANGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 02, 2025	2026 (Q1)	-0.12 / -	-0.11	―	―	―
Jul 15, 2025	2025 (Q4)	-0.12 / -0.03	-0.06	50.00% (+0.03)
Apr 02, 2025	2025 (Q3)	-0.13 / -0.08	-0.16	50.00% (+0.08)
Jan 08, 2025	2025 (Q2)	-0.11 / -0.04	-0.05	20.00% (+0.01)
Oct 03, 2024	2025 (Q1)	-0.15 / -0.11	-0.12	8.33% (<+0.01)
Jul 16, 2024	2024 (Q4)	-0.17 / -0.06	0.02	-400.00% (-0.08)
Apr 04, 2024	2024 (Q3)	-0.15 / -0.16	-0.03	-433.33% (-0.13)
Jan 05, 2024	2024 (Q2)	-0.07 / -0.05	0.01	-600.00% (-0.06)
Oct 04, 2023	2024 (Q1)	-0.13 / -0.12	-0.06	-100.00% (-0.06)
Jul 12, 2023	2023 (Q4)	0.02 / 0.02	0.01	100.00% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 15, 2025	$9.63	$8.65	-10.18%
Apr 02, 2025	$9.66	$10.86	+12.42%
Jan 08, 2025	$9.40	$12.94	+37.66%
Oct 03, 2024	$7.65	$6.37	-16.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.